Navigation Links
ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe
Date:7/28/2014

MUNICH, July 28, 2014 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and other chronic respiratory conditions, has won a permanent injunction in Germany against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting sales of infringing headgear used on APEX WiZARD 210 and 220 masks.  The judgment was entered by the Regional District Court in Munich, is appealable, and applies throughout Germany. 

The permanent injunction continues a preliminary injunction that was entered by the same court on Nov. 12, 2013.  The court rejected APEX's request to stay the injunction and its challenge to the validity of ResMed's patent.  The judgment also requires APEX to forfeit its inventory of infringing products, to report on its sales of the infringing products, and to pay damages to ResMed.ResMed has also filed separate patent infringement lawsuits in the same court seeking damages and permanent injunctions to stop infringement of other ResMed patents. The trials of those cases will occur in the fall of 2014.  The additional accused products are:

  • The APEX iCH and XT Fit CPAP devices
  • The APEX WiZARD 210 and WiZARD 220 masks
  • "ResMed has a global business built on its investment in research and developments, resulting in products sold worldwide that excel in performance, quality and comfort," said David Pendarvis, ResMed global general counsel and chief administrative officer. "We will continue to defend our investment in intellectual property and pursue all legal remedies to prevent infringement in any country where that infringement exists."

    About ResMed: ResMed changes lives by developing, manufacturing and dist
    '/>"/>

    SOURCE ResMed Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents
    2. ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results
    3. ResMeds New Nasal Pillows System is Our Quietest Yet; Ultra-light AirFit P10 Packs Powerful Performance in Just over 1.5 Ounces
    4. ResMed Announces Conference Call And Webcast To Discuss Second Quarter 2014 Results
    5. BMC to protect its rights in patent fight with ResMed
    6. Apex reagiert energisch auf ResMed Patentklage
    7. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
    8. ResMed Inc. Announces Record Financial Results For The Quarter Ended September 30, 2013
    9. ResMeds New Nasal Mask Sets the Bar for Comfort and Performance
    10. ResMed Patent Infringement Case Against BMC Advances: International Trade Commission Agrees to Investigate
    11. Apex Fights Back Against ResMeds Patent Litigation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
    (Date:8/3/2015)... PARK, N.J. , Aug. 3, 2015 ... and secondary endpoints in a phase III study (COMPOSE ... adult patients with chronic non-cancer pain. Naldemedine is an ... is the third Phase III trial in which naldemedine ... Study results showed that a 0.2 mg tablet of ...
    (Date:8/3/2015)... Aug. 3, 2015  Encision Inc. (PK:ECIA), a medical ... stray electrosurgical burns in minimally invasive surgery, today announced ... ended June 30, 2015. The Company posted ... net loss of $213 thousand, or $(0.02) per share. ... for a net loss of $202 thousand, or $(0.02) ...
    Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
    ... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... on the development of zinc finger DNA-binding protein (ZFP) Therapeutics® ... collaborators at the 14th Annual Meeting of the American Society ... in Seattle from May 18-21, 2011. "Sangamo,s ...
    ... Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ), ... clinical data highlighting the safety profile of EXPAREL™ ... the 2011 International Anesthesia Research Society (IARS) Annual ... Comprehensive, program-wide safety data for EXPAREL will be ...
    Cached Medicine Technology:Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 2Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 3Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics® 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 2Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 3Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 4Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting 5
    (Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July ... diet leads to one pound of weight loss may not be accurate. While this system ... to one pound of fat varies – based both on the individual and at what ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to ... related claims in which a claimant alleged to have suffered an arterial blood clot ... birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. ...
    (Date:8/3/2015)... ... August 03, 2015 , ... ... MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate ... BESLER Consulting's campaign for the launch of their Readmissions Analytics product was selected ...
    (Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
    (Date:8/3/2015)... , ... August 03, 2015 , ... ... notes that while an overwhelming number of Hispanics believe people can positively ... overwhelming 70 percent of participants queried said making diet changes was important. Far ...
    Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4
    ... ... the highest honors in the industry. , ... (PRWEB) March 8, 2010 -- The Sturge-Weber Foundation honored renowned dermatologist Dr. David J. Goldberg with ... 2010. Dr. Goldberg is a pioneer in the field of dermatology and director ...
    ... ... ... ... ...
    ... developed a new mathematical approach to analyze molecular data ... when combined with well-established techniques, readily identifies changes in ... potential to distinguish between health and disease states. ... Ph.D., of Stanford University, Calif., the team of investigators ...
    ... Doctors should do more to explain test results, researchers find ... do a better job of explaining genomic test results to ... which analyzes 21 genes in breast tumors removed during surgery ... can help guide decisions about the use of chemotherapy in ...
    ... , ... ... ... ...
    ... , ... ... ... ...
    Cached Medicine News:Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 2Health News:The Sturge-Weber Foundation Honors Dr. David J. Goldberg 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 2Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 3Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 4Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 5Health News:Revisions to Health Care Reform Must Include Rate Freeze, Rate Regulation and States' Rights Provisions, Says Consumer Watchdog 6Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 2Health News:New approach to immune cell analysis seen as first step to better distinguish health and disease 3Health News:Breast Cancer Patients Often Confused by Genomic Testing 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 2Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 3Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 4Health News:Roche/Genentech/Chugai's Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources' Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer 5Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 2Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 3Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 4Health News:Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation 5
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: